RELMADA THERAPEUTICS, INC. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d71ffc65-f0e3-47db-8551-b48cbce2d971/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-59.1M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-031862 |
| FY 2024 | $-83.9M | 2024-01-01 – 2024-12-31 | evidence 0001013762-25-003426 |
| FY 2023 | $-103.7M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-024013 |
| FY 2022 | $-38.3M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-038533 |
| FY 2021 | $-125.7M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-015012 |
| FY 2020 | $-60.8M | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-017556 |
| FY 2019 | $-15.1M | 2019-01-01 – 2019-12-31 | evidence 0001213900-21-017556 |
| FY 2018 | $-6.9M | 2017-07-01 – 2018-06-30 | evidence 0001213900-18-013238 |
| FY 2017 | $-7.2M | 2016-07-01 – 2017-06-30 | evidence 0001213900-17-010097 |
| FY 2016 | $-16.2M | 2015-07-01 – 2016-06-30 | evidence 0001213900-16-016664 |
| FY 2015 | $-17.1M | 2014-07-01 – 2015-06-30 | evidence 0001213900-15-006928 |
| FY 2013 | $-17.1M | 2004-05-25 – 2014-03-31 | evidence 0001213900-14-003773 |
| FY 2012 | $-44.8k | 2011-05-23 – 2013-05-31 | evidence 0001255294-13-000523 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).